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Introduction
Puberty is a transitional period characterized by rapid
physiological changes, including growth spurts and matura-
tion of the gonads and the brain. It entails progression from
the first appearance of secondary sexual characteristics to
full sexual maturation and fertility. While it is known that
the onset of puberty is initiated by awakening of complex
neuroendocrine machinery and an increase in pulsatile sec-
retion of gonadotropin-releasing hormone (GnRH) in the
hypothalamic-pituitary-gonadal (HPG) axis, the primary
mechanisms are incompletely understood. The time of on-
set of puberty and its course are influenced by genetic fac-
tors and are modified by environmental factors, including
socioeconomic factors, nutrition, general health, geography,
altitude, intrauterine conditions, stress, climate conditions,
and the light-dark cycle1). Puberty is considered preco-
cious when the onset of puberty begins before the age of
8 years in girls and before the age of 9 years in boys2).
Precocious puberty is divided into two classes: central
precocious puberty (CPP) and pseudoprecocious puberty.
CPP is caused by premature reactivation of the HPG axis,
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while pseudoprecocious puberty is unrelated to activation
of the HPG axis. In our series of 948 patients referred for
evaluation of signs of precocious puberty, the final diag-
noses were as follows: early puberty (39%), premature
thelarche (31%), CPP (27%), and pseudoprecocious pu-
berty (1%)3). About 95% of precocious puberty is in fe-
males and 90% of CPP in girls is idiopathic3). Children with
precocious puberty may experience problems in growth and
psychosocial development. GnRH analogs (GnRHas) are
standard of care for the treatment of CPP to improve the
final outcome. According to recent reports, an increasing
incidence of advanced pubertal timing is being observed
worldwide. This secular trend of advance is also apparent
in Korean children and adolescents. According to the data
from the Health Insurance Review and Assessment Service
in Korea, the number of patients treated with GnRHas has
surprisingly increased from 226 patients in 2004 to 1,707
patients in 20084). The increasing incidence of precocious
puberty has raised public concerns over health and growth
problems. This review summarizes the optimal use of
GnRHas in children with CPP.
Diagnostic evaluation of CPP
1. Clinical criteria
Precocious puberty can be diagnosed when breast or
pubic hair development begins before the age of 8 years
Clinical application of gonadotropin-releasing hormone
analogs in children and adolescents
Ho-Seong Kim, M.D
Department of Pediatrics, College of Medicine, Yonsei University, Seoul, Korea
= Abstract =
Although the increasing incidence of central precocious puberty (CPP) in Korea has recently raised public concerns about
health and growth problems, there are many areas of uncertainty regarding the pathogenesis, diagnosis, and management
of CPP. In this paper, we review the definition of precocity, the assessment of CPP, and the hormonal abnormalities that
support the diagnosis. In addition, we review the practical guidelines regarding the clinical use of gonadotropin-releasing
hormone analogs in children with CPP. Indications for treatment, determination of dosage, monitoring during treatment,
and discontinuation of therapy are discussed. (Korean J Pediatr 2010;53:294-299)
Key Words : Central precocious puberty, Gonadotropin-releasing hormone analogs, Child, Adolescent
Clinical application of GnRH analogs in children and adolescents
- 295 -
or menstruation begins before the age of 9.5 years in girls
and when testicular enlargement begins before the age of
9 years in boys. Although CPP usually presents with ac-
celerated growth velocity and bone maturation, it does not
present as a homogeneous clinical picture. CPP may be
more appropriately described as a continuum of clinical
presentation and rate of progression, ranging from a nor-
mal variant or transient form to slowly progressive or ra-
pidly progressive forms (Fig. 1)5). Premature thelarche can
progress to progressive CPP. In addition, some forms of
progressive CPP may present an unsustained or undulating
course during progression6, 7). Patients with premature the-
larche or the transient form of CPP and certain patients
with slowly progressive CPP and advanced bone age may
reach normal adult height without administration of GnRHas.
The recognition of progressive pubertal development is the
most important clinical criterion for GnRHas therapy for
avoidance of unnecessary treatment. It is recommended
that documentation of progressive pubertal development
and accelerated growth should be made over a 3- to 6-
month period prior to initiating GnRHas therapy8). This
observational period may not be necessary if the child is
at or past Tanner stage III (breast), particularly with ad-
vanced skeletal maturation8).
2. Hormonal criteria
When the patient is suspected of having precocious pub-
erty on the basis of clinical manifestations, the next steps
for confirming the diagnosis include obtaining measure-
ments of estradiol or testosterone, luteinizing hormone
(LH), and follicle-stimulating hormone (FSH) by high sen-
sitivity-specificity assays. These assays should have a
sensitivity of at least 10 pg/mL for estradiol, 10 ng/dL for
testosterone, and 0.2 IU/L for LH and FSH.
Determination of LH in the serum is the most valuable
test in the diagnosis of CPP. A basal LH higher than 0.2
IU/L suggests evidence of the maturity of the HPG axis.
However, about 53.8% of girls with Tanner stage II have
levels in the prepubertal range, indicating the need for the
GnRH stimulation test to establish the precise diagnosis9).
The GnRH stimulation test can be performed by administra-
tion of GnRH (serial samples at 30 minutes interval for 120
minutes after 100 g intravenous infusion) or a GnRHaμ
such as aqueous leuprolide (single sample at 60 minutes).
Although peak LH levels show an overlap between prepu-
bertal and early pubertal children, a prepubertal limit of
peak LH at 3.3 to 5.0 IU/L has been suggested9, 10). Ac-
cording to the Health Insurance Review and Assessment
Service of Korea, a peak LH higher than 5.0 IU/L can be
considered a pubertal range. In contrast, FSH levels are
not helpful diagnostically. However, the measurements of
the LH/FSH ratio after GnRH stimulation may help to dif-
ferentiate progressive CPP from nonprogressive variants.
Daytime estradiol concentration levels higher than 10
pg/mL in girls or testosterone levels higher than 25 ng/dL
in boys represent pubertal conditions11). However, the
serum level of sex hormone may be fluctuating in the early
pubertal period or in the normal cyclic fashion of CPP.
3. Brain magnetic resonance imaging
Unsuspected intracranial organic lesions in CPP have
been reported in 8% of girls and 40% of boys12, 13). Our
study showed that 10.7% of girls and 42.8% of boys with
CPP had intracranial pathology3). The incidence of intra-
cranial pathology with CPP decreases with age12, 13). Mag-
netic resonance imaging of the sella is indicated in all boys
with CPP, girls less than 6 years of age with CPP, girls
with rapidly progressive CPP, or neurologic findings.
4. Pelvic ultrasonography
Pelvic ultrasonography is helpful for differentiating CPP
from premature thelarche. Girls with CPP have an increased
uterine length (more than 3.4-4.0 cm) and ovarian volume
(more than 1 3 mL) relative to girls in prepubertal period–
or with premature thelarche14, 15). Pelvic ultrasonography
is also indicated to rule out abdominal or pelvic masses
when pseudoprecocious puberty is suspected.Fig. 1. The spectrum of precocious pubertal development ranges
from normal variant or transient form to slowly progressive or
rapidly progressive form.
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Management of CPP
1. Indication for GnRHas
Generally accepted indications for administration of
GnRHas include complete and progressive CPP and com-
promised height potential, deterioration of final adult height
prediction, or expectations of abnormal psychosocial beha-
vior (Table 1)5). From these criteria, it is obvious that care-
ful follow-up examination should be made before a decision
regarding the indication for treatment.
2. Currently available GnRHas
GnRH agonistic analogs were developed throughout the
1970s and 1980s and were first applied in the management
of CPP patients in 198116, 17). GnRHas suppress the serum
levels of LH, FSH and sex steroids within 2 4 weeks by–
continuous stimulation of the pituitary gland, which leads
to downregulation of GnRH receptors and desensitization
of pituitary gonadotrophs. Several preparations of GnRHas
are currently available and are mostly effective. Leuprore-
lin, triptorelin, and goserelin can be used as monthly and
quarterly depot preparations. Histrelin is available as a
12-month implant but currently only in the U.S. Short-
acting preparations administered 1 3 times per day by–
nasal spray are also available. The depot preparations are
preferred because of good compliance and convenience. A
monthly depot preparation is typically used for most chil-
dren with CPP. Table 2 indicates all depot preparations
available in the Korean market, but only 3.75 mg formula-
tions of leuprolide (all brands) and triptorelin (only deca-
peptyl) have been approved by the Korea Food and Drug
Administration as therapeutic agents for the treatment of
CPP. Recently, the quarterly regimen has been reported to
be effective for suppression of the HPG axis18, 19), but a
randomized comparative study has not yet been conducted.
3. Dose of GnRHas
The choice of the optimal dose of GnRHas at the start
of treatment is controversial. A study in Japan, where
leuprolide was first developed, recommended a dose of
more than 30 g/kg to suppress gonadotropinsμ 20). In the
U.S. it is presently recommended to administer 7.5 mg (or
200-300 g/kg) of leuprolide acetate per month subcuμ -
taneously or intramuscularly. In Europe, the dose is 3.75
mg (or 150 g/kg)μ 21). Most pediatric endocrinologists in
Korea use 3.75 mg of leuprolide or triptorelin per month as
a starting dose. More frequent injections or higher doses
may be required in cases with improper suppression of the
HPG axis.
4. Monitoring during treatment
Regular check-ups are recommended for monitoring the
adequacy and efficacy of the treatment. Measurements of
height, weight, growth velocity, and progression of puberty
by the Tanner staging method22) should be made during
each visit. It is also recommended that measurements be
obtained for bone age, basal sex steroid, LH, FSH, and sti-
mulated LH (using GnRH, aqueous GnRHas, or the GnRHas-
containing depot preparations) in order to monitor the pro-
per suppression of hormones within the first 3 months of
treatment and every 6 months thereafter. If there is a pro-
gression of breast size, testicular enlargement, marked de-
creased growth velocity, or rapid bone age advancement, a
prompt reassessment should be conducted. Bone age can be
used to predict the final adult height during treatment by
the Bayley-Pinneau method23). Treatment is considered
adequate if the estradiol level becomes prepubertal24) or if
the peak LH is below 2.3 IU/L after a classical GnRH test
or below 6.6 IU/L 2 hours after administration of depot
Table 1. Suggested Indications for GnRHas
1. Complete precocious puberty
2. Pubertal LH level after GnRH stimulation test above diagnostic
limit (5.0 IU/L)
3. Rapid pubertal development
4. Abnormal height potential
or
5. Loss of height potential during follow-up
and/or
6. Psychosocial/behavioural reasons
Table 2. Depot GnRHas Preparations in Korea
Depot preparation Brand name Dose
Leuprolide
Ttiptorelin
Goserelin
Buserelin
Histrelin
Leuplin
Lucrin
Lorelin
Luphere
Decapeptyl
Diphereline
Zoladex
Superfact
Supprelin
3.75 mg, 11.25 mg
3.75 mg, 11.25 mg
3.75 mg, 11.25 mg
3.75 mg
3.75 mg
3.75 mg, 11.25 mg
3.6 mg, 10.8 mg
5.775 mg
50 mg
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leuprolide
25).
5. Discontinuation of GnRHas
The decision to discontinue GnRHas treatment depends
upon the primary goals of therapy, which may include pre-
vention of short adult height, decreasing psychosocial dis-
tress, and facilitation of care of the developmentally de-
layed child6). In terms of improving the height potential of
girls, discontinuation of the therapy at the chronological age
of 11 years26) or bone age of 12.0 12.5 years of age–
27) is
generally suggested. However, bone age is not an approp-
riate single variable because it is unreliable as a predictor
of height gain after treatment28).
6. Therapeutic agents that can be combined with GnRHas
Growth hormone (GH) can be added if the growth velo-
city falls below the prepubertal normal range during treat-
ment or if patients had begun treatment at a relatively late
stage. Treatment with GH increases adult height relative to
administration of GnRHas alone in patients with CPP and
slow growth velocity. Adjunctive therapies such as estro-
gen receptor blockers, aromatase inhibitors, antiandrogens,
sex steroids, or nonaromatizable anabolic steroids may
improve adult height, but require validation for safety by
further studies8).
7. Adverse reactions
Administration of GnRHas produces relatively minimal
adverse reactions. Headaches and menopausal symptoms
such as hot flashes may be associated with therapy. Local
complications, including sterile abscess, occur in 10% to
15% of patients18). Although there is a concern about the
possible risks of obesity and osteoporosis during and after
treatment, longitudinal studies showed that GnRHas do not
increase the incidence of obesity or osteoporosis29-31).
8. Effect of GnRHas treatment on final height
GnRHas have been used in the treatment of CPP for more
than 25 years, but there are no randomized controlled stu-
dies to estimate the effect of GnRHas treatment on final
height compared with untreated controls. The outcome of
GnRHas treatment on final height can only be evaluated by
comparing the final height in treated patients with historical
data from untreated patients. GnRHas treatment has been
reported to induce a height gain above the pretreatment
height prediction of about 1.4 cm for each year of therapy
32). When GH is added, height gain can be increased to 2.0
cm above the pretreatment height prediction for each year
of therapy
33).
9. Long-term outcome after GnRHas treatment
Long-term studies have reported that gonadal function
is reactivated soon after cessation of treatment. The mean
time for onset of menstruation after discontinuation of
therapy is 16 months (range 2-61 months)31). A regular
ovarian cycle occurred in 60% to 96% of the patients,
which is compatible with the normal pattern of menses at
this age. Infertility has not been reported. There is no
evidence that CPP increases the risk of hirsutism and/or
polycystic ovary syndrome relative to the normal popula-
tion34). Only limited studies are available on the effects of
psychosocial development after GnRHas treatment35). Fur-
ther studies that employ standardized tools are needed.
GnRHas treatment in conditions other than CPP
1. GnRHas treatment in early puberty
Early puberty in girls is defined as onset of puberty at
an age of 8-9 years. Some patients with early puberty may
experience attenuated height potential and psychosocial
problems36). However, routine use of GnRHas in early
puberty is not suggested because the effect of GnRHas on
final height is equivocal and because of the possibility of
additional adverse effects36). GnRHas therapy in early pu-
berty should be restricted to patients for whom a dramatic
decrease in height is predicted. This therapy should be
conducted over a 6-month follow-up period for the ad-
vanced and rapidly progressive forms37).
2. GnRHas treatment in GH deficiency or idiopathic
short stature
Retrospective and prospective studies evaluating the
effect of administering GnRHas with GH in patients with
GH deficiency or idiopathic short stature have provided
controversial results38-40). Combined therapy with GnRHas
and GH in patients with GH deficiency or idiopathic short
stature is not presently suggested8).
Conclusion
GnRHas therapy is the standard treatment modality for
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CPP. The efficacy of treatment on final height is definite
only in rapidly progressive CPP. Careful follow-up exa-
mination is recommended for 3-6 months to determine the
rate of progression before a decision is made regarding
treatment. This observational period may not be necessary
if the patient is at or past Tanner stage III with advanced
bone age. A monthly depot preparation is effective for sup-
pressing the HPG axis and represents the treatment of
choice in most children with CPP. Reverse reactions are of
minor severity and acceptable. There is no evidence that
GnRHas causes obesity, osteoporosis, or severe long-term
sequelae that lead to infertility. GnRHas treatment for con-
ditions other than CPP is not recommended.
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